loading
전일 마감가:
$23.05
열려 있는:
$23.06
하루 거래량:
917.39K
Relative Volume:
0.44
시가총액:
$3.89B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
129.17
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
+3.06%
1개월 성능:
+3.33%
6개월 성능:
+24.53%
1년 성능:
+25.34%
1일 변동 폭
Value
$22.86
$23.39
1주일 범위
Value
$22.09
$23.60
52주 변동 폭
Value
$13.40
$25.23

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
명칭
Acadia Pharmaceuticals Inc
Name
전화
858-558-2871
Name
주소
12830 EL CAMINO REAL, SAN DIEGO
Name
직원
654
Name
트위터
@acadiapharma
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
ACAD's Discussions on Twitter

ACAD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
23.25 3.86B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-21 업그레이드 Deutsche Bank Hold → Buy
2025-02-11 개시 Deutsche Bank Hold
2025-01-03 다운그레이드 Guggenheim Buy → Neutral
2024-10-10 재개 Raymond James Mkt Perform
2024-08-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-06-27 개시 BMO Capital Markets Outperform
2024-03-12 다운그레이드 Mizuho Buy → Neutral
2024-03-12 재확인 Needham Buy
2024-01-30 개시 Robert W. Baird Outperform
2024-01-24 업그레이드 Needham Hold → Buy
2023-12-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-12-14 다운그레이드 Deutsche Bank Buy → Hold
2023-12-13 개시 Citigroup Buy
2023-12-12 개시 Deutsche Bank Buy
2023-11-06 업그레이드 Mizuho Neutral → Buy
2023-10-17 개시 UBS Buy
2023-10-10 업그레이드 JP Morgan Neutral → Overweight
2023-01-03 업그레이드 Guggenheim Neutral → Buy
2022-11-04 다운그레이드 Goldman Neutral → Sell
2022-11-01 개시 Loop Capital Hold
2022-08-08 다운그레이드 Citigroup Buy → Neutral
2022-08-05 다운그레이드 Citigroup Buy → Neutral
2022-06-21 다운그레이드 Jefferies Buy → Underperform
2022-06-16 업그레이드 Jefferies Hold → Buy
2022-03-16 업그레이드 Canaccord Genuity Hold → Buy
2022-02-09 업그레이드 H.C. Wainwright Neutral → Buy
2022-01-05 업그레이드 Citigroup Neutral → Buy
2021-12-21 다운그레이드 Guggenheim Buy → Neutral
2021-11-01 업그레이드 Guggenheim Neutral → Buy
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-06-10 개시 Berenberg Hold
2021-04-07 다운그레이드 H.C. Wainwright Buy → Neutral
2021-04-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-04-06 다운그레이드 Goldman Buy → Neutral
2021-04-06 다운그레이드 Jefferies Buy → Hold
2021-04-06 다운그레이드 Mizuho Buy → Neutral
2021-04-05 다운그레이드 Raymond James Outperform → Mkt Perform
2021-03-10 다운그레이드 BofA Securities Buy → Neutral
2021-03-09 다운그레이드 Citigroup Buy → Neutral
2021-03-09 다운그레이드 Guggenheim Buy → Neutral
2021-03-09 재확인 H.C. Wainwright Buy
2021-03-09 다운그레이드 Raymond James Strong Buy → Outperform
2021-03-09 다운그레이드 Stifel Buy → Hold
2020-12-16 개시 Mizuho Buy
2020-11-16 업그레이드 Raymond James Outperform → Strong Buy
2020-08-25 개시 Raymond James Outperform
2020-08-20 개시 Morgan Stanley Overweight
2020-07-07 업그레이드 Stifel Hold → Buy
2020-04-16 개시 Jefferies Buy
2020-03-31 업그레이드 Goldman Neutral → Buy
2020-03-06 개시 Citigroup Buy
2019-12-16 개시 Guggenheim Buy
2019-10-24 개시 Oppenheimer Perform
2019-10-01 개시 RBC Capital Mkts Outperform
2019-09-13 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-09-10 업그레이드 Canaccord Genuity Hold → Buy
2019-07-23 재확인 Needham Buy
2018-12-10 개시 Canaccord Genuity Hold
2018-09-21 업그레이드 Piper Jaffray Neutral → Overweight
2018-08-09 재확인 Stifel Hold
2018-08-07 개시 Stifel Hold
2018-08-06 다운그레이드 Piper Jaffray Overweight → Neutral
2017-10-06 재개 Goldman Neutral
모두보기

Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스

pulisher
Jul 26, 2025

Why ACADIA Pharmaceuticals Inc. stock attracts strong analyst attentionBreakout Momentum Stocks - Metal.it

Jul 26, 2025
pulisher
Jul 26, 2025

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - 富途牛牛

Jul 26, 2025
pulisher
Jul 25, 2025

What risks could impact ACADIA Pharmaceuticals Inc. stock performanceFree Investment Risk Control - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives ACADIA Pharmaceuticals Inc. stock priceHigh-yield portfolio picks - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

ACADIA Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about ACADIA Pharmaceuticals Inc. stockPowerful profit generation - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is ACADIA Pharmaceuticals Inc. a good long term investmentTremendous return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN

Jul 19, 2025
pulisher
Jul 17, 2025

Bank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Jul 17, 2025
pulisher
Jul 15, 2025

Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

What makes ACADIA Pharmaceuticals Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru

Jul 14, 2025
pulisher
Jul 10, 2025

The $12 Billion Opportunity Bolstering This Biotech Stock - Investor's Business Daily

Jul 10, 2025
pulisher
Jul 07, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com Australia

Jul 07, 2025
pulisher
Jul 03, 2025

Acadia Pharmaceuticals Rides High On Patent Wins And Strong Pipeline - Finimize

Jul 03, 2025
pulisher
Jul 03, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 03, 2025
pulisher
Jul 02, 2025

Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline - BioPharma Dive

Jul 02, 2025
pulisher
Jun 29, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Jun 29, 2025
pulisher
Jun 27, 2025

Acadia Pharmaceuticals' Stocks Undervalue Future Blockbuster Potential - Finimize

Jun 27, 2025
pulisher
Jun 26, 2025

ACAD: ACADIA Pharmaceuticals Receives Buy Rating from Needham | ACAD Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Stocks With Rising Composite Ratings: ACADIA Pharmaceuticals - Investor's Business Daily

Jun 26, 2025
pulisher
Jun 25, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers - Business Wire

Jun 25, 2025
pulisher
Jun 24, 2025

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know - Nasdaq

Jun 23, 2025
pulisher
Jun 23, 2025

Learn to Evaluate (ACAD) using the Charts - news.stocktradersdaily.com

Jun 23, 2025
pulisher
Jun 20, 2025

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent - MSN

Jun 20, 2025
pulisher
Jun 18, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com

Jun 18, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule. - AInvest

Jun 17, 2025
pulisher
Jun 14, 2025

Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey

Jun 11, 2025

Acadia Pharmaceuticals Inc (ACAD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):